

Paroxysmal Nocturnal Hemoglobinuria

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition

Trial Status
Active, not recruiting

Trial Runs In
1 Countries

Trial Identifier
NCT04654468 YO42311

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will enrol participants aged 12 years or older with a body weight \geq 40 kilograms (kg) diagnosed with PNH who have not been previously treated with complement inhibitor therapy. Approximately 50 participants will be treated with Crovalimab for at least 24 weeks.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT04654468 YO42311
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
 \geq 12 Years

Healthy Volunteers
No
